French-American company that deals with food safety, quality and sustainability Merieux NutriSciences announced on Monday that it has completed the acquisition of France-based testing and inspection organisation Bureau Veritas' food testing activities in Japan, Morocco, Southeast Asia and South Africa.
Following the recent finalisation of the deal in Canada and the US, this latest wave of closings marks a significant milestone in the previously announced global transaction, strengthening Mérieux NutriSciences' global position in food testing, inspection and certification (TIC).
This phase of the acquisition allows Merieux NutriSciences to establish a strong presence in the Japanese, Moroccan and Southeast Asian markets. The transaction also improves its capabilities in South Africa, including the addition of pharmaceutical testing solutions.
With the transaction, Merieux NutriSciences has included over 500 employees and integrated eight laboratories into its global network. This transaction is part of a broader agreement with Bureau Veritas encompassing its worldwide food laboratory testing activities, which include microbiological and chemical analysis, as well as molecular testing. Additional announcements about the completion of acquisitions in other regions, including laboratories across Asia-Pacific and Latin America, will follow as those transactions are finalised.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA